ENTERPRISE SENIOR VICE PRESIDENT, PROFESSOR AND CHAIR OF ENTERPRISE RADIATION ONCOLOGY, SIDNEY KIMMEL CANCER CENTER, SIDNEY KIMMEL MEDICAL COLLEGE, THOMAS JEFFERSON UNIVERSITY
Adam Dicker, is Enterprise Senior Vice President, Professor and Chair of Enterprise Radiation Oncology, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia PA.
Dr. Dicker’s work has resulted in the establishment of parameters for quality assurance in radiation oncology, robotic technologies for brachytherapy, novel therapeutic clinical trials utilizing targeted therapies and ionizing radiation, innovative preclinical models to evaluate radiation modifiers including immunotherapy and FDA/CMS approval of a genomic classifier for management of prostate cancer.
His research is focused on collection of PROs and remote activity monitoring for patients receiving chemo-radiation, molecular targeted therapies and immunotherapy and are expanding to the non-oncology patient population. Dr. Dicker’s research supported by the Prostate Cancer Foundation is focused on radiation-immunotherapy approaches integrated with digital health technologies to improve the lives of patients.
Dr. Dicker leads a University-wide effort in Digital Health and Data Science, using the convergence of mobile technology, platforms, networks, and machine learning to improve the lives of patients. The Jefferson Institute of Digital Health focuses and further develop Jefferson’s digital health strategy and footprint. It houses medical student, graduate degree programs and post graduate education, coordinates research and development activities, and develops critical industry partnerships related to digital health across the Jefferson Health System.
Dr. Dicker is Chair Emeritus, Integration Panel for the Prostate Cancer Research Program-Department of Defense, Vice-Chair, Translational Science and Digital Health committees for NRG Oncology (www.nrgoncology.org), and Radiation Oncology Co-Chair, NCI Genitourinary Cancers Prostate Cancer Task Force. He is a member of the National Cancer Institute Investigational Drug Steering Committee, and National Clinical Trial Network Core Correlative Sciences Committee. Dr. Dicker has authored and co-authored over 320 papers in professional journals, 4 textbooks and numerous book chapters. He was elected a Fellow of the American Society of Radiation Oncology in 2014.
Dr. Dicker received his BA from Columbia College, and his MD and PhD (Molecular Pharmacology) from Cornell University Medical College. He received his postgraduate training at Memorial Sloan-Kettering Cancer Center after a surgical internship.